Zakrzewski Joseph S
Zakrzewski Joseph S's purchase track record
How the stock did after each of Zakrzewski Joseph S's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/27/2024 | ANTX | $3K | -17.5% | -16.1% | -1.8% |
| 11/18/2024 | ANTX | $25K | +14.0% | +19.0% | +1.2% |
| 12/14/2021 | AMRN | $39K | -11.7% | -45.2% | -19.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Amarin (AMRN) sees competition as Teva pushes branded drugs. Teva Pharmaceutical announced that branded drugs will be a central part of its growth plan. This focus highlights the competitive environment for other companies with specialty branded products, such as Amarin’s Vascepa. The news may influence market perception of Amarin’s positioning within the branded drug space.
Transaction History
| ANTX | ▼ Sell | Gift | 405,880 | $0 | 8/14/2026 | View on chart |
| ANTX | ▲ Buy | Grant | 10,523 | $0 | 4/10/2025 | View on chart |
| ANTX | ▲ Buy | Grant | 9,816 | $0 | 12/19/2024 | View on chart |
| ANTX | ▲ Buy | Open Market | 2,000 | $3K | 11/27/2024 | View on chart |
| ANTX | ▲ Buy | Open Market | 5,000 | $5K | 11/19/2024 | View on chart |
| ANTX | ▲ Buy | Open Market | 20,000 | $20K | 11/18/2024 | View on chart |
| ANTX | ▼ Sell | Open Market | 100,000 | $1.9M | 1/18/2024 | View on chart |
| ANTX | ▼ Sell | Other | 98,199 | — | 3/29/2022 | View on chart |
| AMRN | ▲ Buy | Open Market | 2,000 | $6K | 12/15/2021 | View on chart |
| AMRN | ▲ Buy | Open Market | 10,000 | $33K | 12/14/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
AN2 Therapeutics: Failed Drug Potential Value Driver
Seeking Alpha reports that a previously failed drug from AN2 Therapeutics may become a significant value driver for the company. This development is relevant as it suggests potential new revenue or licensing opportunities. The stock is currently trading near its support level, with an average analyst target of $9.00.
AN2 Therapeutics: Failed Drug Potential Value Driver. Seeking Alpha reports that a previously failed drug from AN2 Therapeutics may become a significant value driver for the company. This development is relevant as it suggests potential new revenue or licensing opportunities. The stock is currently trading near its support level, with an average analyst target of $9.00.